Not all antibodies are equal

door Booth, Laurence
Gepubliceerd in 2013

Repurposing Tecfidera for cancer

door Booth, Laurence, Malkin, Mark, Dent, Paul
Gepubliceerd in Aging (Albany NY) (2016)

Not the comfy chair! Cancer drugs that act against multiple active sites

door Booth, Laurence, Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Expert Opin Ther Targets (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies

door Dent, Paul, Booth, Laurence, Poklepovic, Andrew
Gepubliceerd in Immunometabolism (2019)

HSPA5/Dna K May Be a Useful Target for Human Disease Therapies

door Booth, Laurence, Roberts, Jane L., Dent, Paul
Gepubliceerd in DNA Cell Biol (2015)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species

door Roberts, Jane L., Poklepovic, Andrew, Booth, Laurence
Gepubliceerd in Oncotarget (2017)

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

door Booth, Laurence, Roberts, Jane, Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Cancer Biol Ther (2018)

The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib

door Booth, Laurence A., Roberts, Jane L., Dent, Paul
Gepubliceerd in Semin Cancer Biol (2019)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]

door Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Oncotarget (2017)

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells

door Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Cancer Biol Ther (2017)

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody

door Booth, Laurence, Roberts, Jane Lisa, Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Cancer Biol Ther (2018)

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells

door Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Oncol Signal (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib

door Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Front Oncol (2019)

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

door Booth, Laurence, West, Cameron, Hoff, Daniel Von, Dent, Paul
Gepubliceerd in Front Oncol (2020)

Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

door Booth, Laurence, West, Cameron, Von Hoff, Daniel, Dent, Paul
Gepubliceerd in Front Oncol (2021)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic

door Tavallai, Mehrad, Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Front Oncol (2016)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

door Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Gordon, Sarah, Dent, Paul
Gepubliceerd in Oncotarget (2016)

HDAC inhibitors enhance the immunotherapy response of melanoma cells

door Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Dent, Paul
Gepubliceerd in Oncotarget (2017)

Valproate augments Niraparib killing of tumor cells

door Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Cancer Biol Ther (2018)

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells

door Booth, Laurence, Roberts, Jane L., Kirkwood, John, Poklepovic, Andrew, Dent, Paul
Gepubliceerd in Adv Cancer Res (2018)